Referencias

1. Anuario Estadístico. Dirección Nacional de Estadísticas. Ministerio de Salud Pública de Cuba, 2009.
2. World Health Organization. Fifty-eighth World Health Assembly, resolution WHA 58.22, Cancer Prevention and Control. Geneva, Switzerland: World Health Organization, 2005.
3. Bombardieri E, Crippa F, Maffioli L, Greco M. Nuclear medicine techniques for the study of breast cancer. Eur J Nucl Med 1997;24:809-24.
4. Waxman AD, Aktolun C. Breast cancer. In Aktolun C, Tauxe Wn (Eds.) Nuclear Oncology. Berlin, Heideberg, New York: Springer; 1999:143-62.
5. Taillefer R. The role of ^99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 1999;29:16-40.
6. Prats EP, García López F, Dolores Abós M et al. Gamagrafía de mama. Rev Esp Med Nucl 2001;20:47-67.
7. Peña Y, Peña A, Coca MA, Batista JF. Utilidad de la gamagrafía con ^99mTc-MIBI como complemento de la mamografía en pacientes con sospecha de cáncer de mama de un área de salud de Ciudad Habana, Cuba. Alasbimn Journal 8(31): January 2006. Artic
8. Richter JA, García-Velloso MJ, Domínguez I, Quincoces G, Prieto E, Rodríguez Fraile M. Tomografía por emisión de positrones en el cáncer de mama. Rev Med Univ Navarra 2008; 52:4-12.
9. Avendaño, MC. (Coord.). Introducción a la química farmacéutica (3ª reimp.). Interamericana-McGraw-Hill. Madrid, 1996.
10. Devlin, TM. (Ed.). Bioquímica. Libro de texto con aplicaciones clínicas (Tomos I y II) (2ª edición). Editorial Reverté, SA. Barcelona, 1988.
11. Giralt M, Lafuente A, Pujol F, Mallol J. Enhanced S-transferasa activity and gluthatione content in human bladder cancer. Follow-up study: influence of smoking. J Urol 1993;149:1252-54.
12. Bia F, Nakanishi Y, Kawasaki M, et al. Immunohistochemical expression of gluthatione s-transferase-pi can predict chemotherapy response in patients with non-small cell lung carcinoma. Cancer 1996;78:416-21.
13. Wang AY, Liu RS. Evaluation of the biodistribution and in vivo biochemistry of ^99mTc-cysteine and ^99/99mTc-cysteine complexes. A potential renal imaging agent. Nucl Med Biol 1995;22:937-42.
14. Quián YP, Pérez MAC, Pintado AP, Batista JF. Scintigraphic images of breast cancer with Tc-^99m Cysteine. Clin Nucl Med 2006;31:357-8.
15. Noguera EC, Palazzo E, Borello A et al. ^99mTc-Cisteina-Glucosamina (^99mTc-CG) en la evaluación de pacientes con tumores malignos. Correlación histopatológica. Alasbimn Journal 2006;32.
16. Zhang SM, Willett WC, Selhub J et al. A prospective study of plasma total Cysteine and risk of breast cancer. Cancer Epidemiology Biomarkers & Prevention 2003;12:1188-93.
17. Jager PL, Meijer WG, Kema IP et al. L-3-[123I]Iodo-alpha-methyltyrosine scintigraphy in carcinoid tumors: correlation with biochemical activity and comparison with [111In-DTPA-D-Phe1]-octreotide imaging. J Nucl Med 2000;41:1793-800.
18. Mathieu I, Mazy S, Willemart B et al. Inconclusive triple diagnosis in breast cancer imaging: is there a place for scintimammography? J Nucl Med 2005;46:1574-81.
19. Dunnwald LK, Gralow JR, Ellis GK et al. Residual tumor uptake of [^99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 2005;103:680-8.
20. Niikura N, Ueno NT. The Role of 18F-FDG Positron Emission Tomography/Co
21. De Cicco C, Cremonesi M, Luini A et al: Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998;39:2080-4.
22. Ercan MT, Gülaldi NC, Uysal U et al. Accumulation of ^99mTc-Cysteine in experimental inflammatory lesions in comparison to ^99mTc-glutamine and ^99mTc-HIG. Nuklearmedizin 1997;36:265-9.
23. Bae KT, Piwnica-Worms D. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Q J Nucl Med 1997;41:101-10.
24. Mulero F, Nicolas F, Roca V et al. Utilidad de la cuantificación de la captación del [^99mTc] MIBI en neoplasias mamarias en la valoración preoperatorio de la agresividad tumoral. Rev Esp Med Nucl 2000;19:984-7.
25. Marshall C, Eremin J, El-Sheemy M et al. Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (^99m)Tc-Sestamibi uptake. Nucl Med Commun 2005;26:9-15.
26. Gupta P, Waxman A, Nguyen K et al. Correlation of Tc-^99m-sestamibi uptake with histopathologic characteristics in patients with benign breast disease. J Nucl Med 1996;37:250.
27. Papantoniou V, Koutsikos J, Sotiropoulou M et al. Scintimammographic findings of phyllodes tumor of the breast in a double-phase study with Tc-^99m (V) DMSA and Tc-^99m MIBI: a case report. Jpn J Clin Oncol 2004;34:429-31.